- US government contracts for approximately $1 billion (USD) now in place to purchase sotrovimab, further expanding access nationwide
- This brings the total number of doses secured through binding agreements to more than 750,000 globally
- Final data from the COMET-ICE Phase III trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease
- In vitro data indicate sotrovimab maintains activity against the Delta variant of concern and other variants being monitored
GlaxoSmithKline plc (LSE/ NYSE GSK) and Vir Biotechnology,Inc. (Nasdaq VIR) moment blazoned US government contracts totalling roughly$ 1 billion (1) (USD) to buy sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Exigency Use Authorization (EUA) in May 2021. GSK will supply these boluses to the US government by December 17, 2021, enabling further expanded civil access to sotrovimab for cases.
GSK and Vir are committed to ongoing evaluation of sotrovimab as the COVID-19 geography continues to evolve at different rates across the globe and new variants of concern and interest crop. Streamlined in vitro data, published in bioRxiv, demonstrate that sotrovimab retains exertion against all current variants of concern and interest of the SARS-CoV-2 contagion as defined by the World Health Organization, plus others, including, but not limited to, Delta (B.1.617.2), Delta Plus (AY.1 or AY.2) and Mu (B.1.621).
Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 that’s participated with SARS-CoV-1 (the contagion that causes SARS), indicating that the epitope is largely conserved, which may make it more delicate for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend ™ technology, has also been designed to achieve high attention in the lungs to insure optimal penetration into airway apkins affected by SARS-CoV-2 and to have an extended half- life.
About global access to sotrovimab
Sotrovimab is authorised for exigency use in the United States and entered a positive scientific opinion under Composition 5 (3) of Regulation726/2004 from the Committee for Human Medicinal Products (CHMP) in the European Union (EU). Sotrovimab has been granted a provisional marketing authorisation in Australia and a tentative marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Blessing for Exigency Pathway. Temporary authorisations have been granted in Bahrain, Brazil, Canada, Egypt, Italy, Kuwait, Oman, Qatar, Singapore, Switzerland, Thailand and the United Arab Emirates (UAE).
Sotrovimab is supplied in several countries around the world, including through public agreements in the United States, Japan, Australia, Canada, Singapore and the UAE. We’ve also inked a Common Procurement Agreement with the European Commission to supply boluses of sotrovimab. Fresh agreements are yet to be blazoned due to confidentiality or nonsupervisory conditions.
About the Vir and GSK Collaboration
In April 2020, Vir and GSK entered into a collaboration to probe and develop results for coronaviruses, including SARS-CoV-2, the contagion that causes COVID-19. The collaboration uses Vir’s personal monoclonal antibody platform technology to accelerate being and identify newanti-viral antibodies that could be used as remedial or preventative options to help address the current COVID-19 epidemic and unborn outbreaks. The companies will work GSK’s moxie in functional genomics and combine their capabilities in CRISPR webbing and artificial intelligence to identifyanti-coronavirus composites that target cellular host genes. They will also apply their concerted moxie to probe SARS-CoV-2 and other coronavirus vaccines.
GSK Commitment to Diving COVID-19
GSK’s response to COVID-19 has been one of the broadest in the assiduity, with implicit treatments in addition to our vaccine campaigners in development with mate organisations.
GSK is uniting with several organisations on COVID-19 vaccines by furnishing access to our adjuvant technology. We’re working with Sanofi, Medicago and SK bioscience to develop adjuvanted, protein- grounded vaccine campaigners, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular significance in a epidemic since it may reduce the quantum of vaccine protein needed per cure, allowing further vaccine boluses to be produced and contributing to cover further people in need.
GSK is also working with mRNA specialist, CureVac, to concertedly develop coming generation, optimised mRNA vaccines for COVID-19 with the eventuality to address multiple arising variants in one vaccine.
Vir’s Commitment to COVID-19
Vir was innovated with the charge of addressing the world’s most serious contagious conditions. In 2020, Vir responded fleetly to the COVID-19 epidemic by using our unique scientific perceptivity and assiduity leading antibody platform to explore multiple monoclonal antibodies as implicit remedial or preventative options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was precisely named for its demonstrated pledge in preclinical exploration, including an anticipated high hedge to resistance and implicit capability to both block the contagion from entering healthy cells and clear infected cells. Vir is continuing to pursue new remedial and precautionary results to combat SARS-CoV-2 and unborn coronavirus afflictions, both singly and in collaboration with its mates.
GSK is a wisdom- led global healthcare company.
We’re a wisdom- led global healthcare company with a special purpose to ameliorate the quality of mortal life by helping people do more, feel more, live longer.
About Vir Biotechnology
Vir Biotechnology is a marketable- stage immunology company concentrated on combining immunologic perceptivity with slice- edge technologies to treat and help serious contagious conditions. Vir has assembled four technology platforms that are designed to stimulate and enhance the vulnerable system by exploiting critical compliances of natural vulnerable processes. Its current development channel consists of product campaigners targeting COVID-19, hepatitis B contagion, influenza A and mortal immunodeficiency contagion.
Source link: https://www.gsk.com/